What is CareSyntax?
Founded in 2013, CareSyntax operates at the intersection of medical technology and hospital operations. The company provides a comprehensive suite of solutions designed to reduce surgical risk by integrating IoT devices with advanced data analytics. By transforming raw clinical data into meaningful operational intelligence, CareSyntax enables healthcare providers to streamline workflows, improve patient outcomes, and reduce the financial burden associated with surgical complications. Its market position is defined by its ability to bridge the gap between complex surgical environments and digital transformation, making it an essential partner for modern healthcare institutions seeking to optimize their surgical departments.
How much funding has CareSyntax raised?
CareSyntax has raised a total of $433.4M across 6 funding rounds:
Private Equity
$11.9M
Unspecified
$20M
Series B
$45.6M
Other Financing Round
$45.6M
Debt
$350K
Series C
$310M
Private Equity (2017): $11.9M with participation from Norgine
Unspecified (2018): $20M led by Surgical
Series B (2019): $45.6M, investors not publicly disclosed
Other Financing Round (2019): $45.6M featuring Whiz Partners, Plug and Play, Mitsubishi Corporation, IPF Partners, Barco Healthcare, and Relyens
Debt (2020): $350K backed by PPP
Series C (2024): $310M with participation from Relyens Group, Rezayat Group, Vesalius Biocapital, Optum Ventures, Intel Capital, Surgical.Ai, IPF Partners, PFM Health Sciences, Plug and Play Tech Center, Arno Capital Partners, Lauxera Capital Partners, and Symbiotic Capital
Key Investors in CareSyntax
Intel Capital
A division of Intel, this firm invests in innovative startups targeting artificial intelligence, cloud computing, and next-generation compute technologies.
Optum Ventures
A strategic investment arm focused on early-stage companies poised to disrupt the status quo and improve healthcare outcomes for all.
Lauxera Capital Partners
An independent international investment fund specializing in growth-stage Healthtech businesses, focusing on medical devices, digital health, and diagnostics.
What's next for CareSyntax?
With the infusion of $310M, CareSyntax is well-positioned to scale its enterprise-level operations and expand its footprint in the global healthcare market. The company is expected to focus on deepening its integration with existing hospital infrastructure while potentially exploring new frontiers in AI-driven surgical decision support. As the demand for data-driven clinical efficiency continues to rise, CareSyntax is poised to leverage its robust capital base to maintain its competitive edge, drive further innovation in surgical safety, and solidify its role as a critical component of the modern digital hospital architecture.
See full CareSyntax company page
